Cargando…
Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy
Resistance to cancer therapy is a challenge because of innate tumor heterogeneity and constant tumor evolution. Since the pathway of resistance cannot be predicted, combination therapies may address this progression. We discovered that in addition to IGF1 and IGF2, IGFBP-3 binds bFGF, HGF, neureguli...
Autores principales: | Wang, Elizabeth A., Chen, Wan-Yu, Wong, Chi-Huey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026407/ https://www.ncbi.nlm.nih.gov/pubmed/32066763 http://dx.doi.org/10.1038/s41598-020-59466-6 |
Ejemplares similares
-
Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization
por: Dennison, GJ, et al.
Publicado: (2008) -
Activation of insulin-epidermal growth factor (EGF) receptor chimerae regulates EGF receptor binding affinity
Publicado: (1992) -
The Soluble Heparin-Binding EGF-Like Growth Factor Stimulates EGF Receptor Trafficking to the Nucleus
por: Korotkevych, Nataliia V., et al.
Publicado: (2015) -
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
por: Suzuki, Hiroyuki, et al.
Publicado: (2023) -
Role of Insulin-like Growth Factor, Insulin-like Growth Factor Receptors, and Insulin-like Growth Factor-binding Proteins in Ovarian Cancer
por: Amutha, Periyasamy, et al.
Publicado: (2017)